BioVersys AG: Multi Drug Resistant Tuberculosis (TB) has become a serious health threat worldwide. The project aims at overcoming drug resistance against an old antibiotic that is commonly used in the treatment of TB (Ethionamide) and at the same time render the bioactivation of Ethionamide even more efficient in order to be able to use lower doses for the patient. The team targets transcriptional regulators (DNA binding proteins) with their proprietary small chemical compounds and thus render the bioactivation of Ethionamide very efficient and eliminate resistance against the molecule.

PathMaker Neurosystems is a clinical-stage neurotechnology company developing non-invasive systems for the treatment of patients with paralysis, muscle weakness and spasticity. Based on Coordinated Multi-site Neurostimulation, our technology enables directionally-controllable modulation of spinal pathways that have been damaged from neurological disease or trauma. The team is working with world-class research institutions including ICM in France, and have human clinical trials now underway.

Sylvain Celanire

Pragma Therapeutics

Arnab Chakraborty

Flow MedTech, Inc.

Paul Chaney

PanOptica, Inc.

Yves Decadt

Medimetrics Personalized Drug Delivery B.V.

Marc Gitzinger

BioVersys AG

Mike Mace

Imperial College London

Nader Yaghoubi

PathMaker Neurosystems International SAS